Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Современные возможности топической терапии микоза стоп
Современные возможности топической терапии микоза стоп
Максимов И.С. Современные возможности топической терапии микоза стоп. Consilium Medicum. 2020; 22 (7): 57–59. DOI: 10.26442/20751753.2020.7.200322
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Микоз стоп является одним из наиболее распространенных кожных заболеваний. Частота встречаемости в общей популяции составляет от 5 до 20%. Основные возбудители микоза стоп – дерматофиты, на их долю приходится 80–90% случаев. Тербинафин – противогрибковый препарат группы аллиламинов, обладающий широким спектром противогрибковой активности. Он зарегистрирован с 1991 г. в Европе и включен в Список основных лекарственных средств Всемирной организации здравоохранения. В статье рассмотрены особенности применения различных лекарственных форм тербинафина в зависимости от клинической картины микоза стоп. Представлены российские и зарубежные данные об эффективности и безопасности применения тербинафина в топической терапии микоза стоп.
Ключевые слова: тербинафин, микоз стоп, местная терапия.
Key words: terbinafine, foot mycosis, local therapy.
Ключевые слова: тербинафин, микоз стоп, местная терапия.
________________________________________________
Key words: terbinafine, foot mycosis, local therapy.
Полный текст
Список литературы
1. Woodfolk JA. Allergy and dermatophytes. Clin Microbiol Rev 2005; 18 (1): 30–43. DOI: 10.1128/CMR.18.1.30-43.2005
2. Al Hasan M, Fitzgerald SM, Saoudian M, Krishnaswamy G. Dermatology for the practicing allergist: Tinea pedis and its complications. Clin Mol Allergy 2004; 2 (1): 5. DOI: 10.1186/1476-7961-2-5
3. Соколова ТВ, Малярчук ТА. Эпидемиология микозов стоп (Обзор литературы). Эпидемиология и вакцинопрофилактика. 2015; 13 (1): 70–4.
[Sokolova TV, Maliarchuk TA. Epidemiologiia mikozov stop (Obzor literatury). Epidemiologiia i vaktsinoprofilaktika. 2015; 13 (1): 70–4 (in Russian).]
4. Hay RJ, Campbell CK, Wingfield R, Clayton YM. A comparative study of dermatophytosis in coal miners and dermatological outpatients. Br J Ind Med 1983; 40 (3): 353–5. DOI: 10.1136/oem.40.3.353
5. Noguchi H, Hiruma M, Kawada A et al. Tinea pedis in members of the Japanese Self-defence Forces: relationships of its prevalence and its severity with length of military service and width of interdigital spaces. Mycoses 38 (11–12): 494–9. http://www.ncbi.nlm.nih.gov/pubmed/8720203
6. Lacroix C, Baspeyras M, de La Salmonière P et al. Tinea pedis in European marathon runners.
J Eur Acad Dermatol Venereol 2002; 16 (2): 139–42. DOI: 10.1046/j.1468-3083.2002.00400.x
7. Djeridane A, Djeridane Y, Ammar-Khodja A. Epidemiological and aetiological study on tinea pedis and onychomycosis in Algeria. Mycoses 2006; 49 (3): 190–6. DOI: 10.1111/j.1439-0507.2006.01230.x
8. Dhib I, Fathallah A, Yaacoub A et al. Clinical and mycological features of onychomycosis in central Tunisia: a 22 years retrospective study (1986–2007). Mycoses 2013; 56 (3): 273–80. DOI: 10.1111/myc.12016
9. Drakensjö IT, Chryssanthou E. Epidemiology of dermatophyte infections in Stockholm, Sweden:
a retrospective study from 2005–2009. Med Mycol 2011; 49 (5): 484–8. DOI: 10.3109/13693786.2010.540045
10. Alvarez MI, González LÁ, Castro LÁ. Onychomycosis in Cali, Colombia. Mycopathologia 2004;
158 (2): 181–6. DOI: 10.1023/B: MYCO.0000041866.85314.e4
11. Рукавишникова ВМ. Микозы стоп. М.: Эликс Ком, 2003.
[Rukavishnikova VM. Mycoses of the feet. Moscow: Elix Kom, 2003 (in Russian).]
12. Яковлев А.Б. Эффективность и безопасность тербинафина при комбинированной терапии разных клинических форм микоза стоп. Эффективная фармакотерапия. 2018; 21: 4–9.
[Iakovlev A.B. Effektivnost' i bezopasnost' terbinafina pri kombinirovannoi terapii raznykh klinicheskikh form mikoza stop. Effektivnaia farmakoterapiia. 2018; 21: 4–9 (in Russian).]
13. Favre B, Ryder NS. Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother 1996; 40 (2): 443–7. DOI: 10.1128/aac.40.2.443
14. Sugiura M, Hata Y, Fukuda T et al. One-week application of terbinafine cream compared with four-week application in treatment of Tinea pedis. Nihon Ishinkin Gakkai Zasshi 2001; 42 (4): 223–8. DOI: 10.3314/jjmm.42.223
15. Ablon G, Rosen T, Spedale J. Comparative efficacy of naftifine, oxiconazole, and terbinafine in short-term treatment of tinea pedis. Int J Dermatol 1996; 35 (8): 591–3. DOI: 10.1111/j.1365-4362.1996.tb03668.x
16. Хамаганова И.В., Цыкин А.А. Раствор тербинафина 1% пленкообразующий в терапии у пациентов, длительно страдающих микозами стоп. Мед. совет. 2019; 12: 132–5.
[Khamaganova I.V., Tsykin A.A. Rastvor terbinafina 1% plenkoobrazuiushchii v terapii u patsientov, dlitel'no stradaiushchikh mikozami stop. Med. sovet. 2019; 12: 132–5 (in Russian).]
17. Li RY, Wang AP, Xu JH et al. Efficacy and safety of 1% terbinafine film-forming solution in Chinese patients with tinea pedis: a randomized, double-blind, placebo-controlled, multicenter, parallel-group study. Clin Drug Investig 2014; 34 (3): 223–30. DOI: 10.1007/s40261-014-0171-8
18. Ortonne J, Korting H, Viguié-Vallanet C et al. Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athlete’s foot): a randomized, double-blind, placebo-controlled study. J Eur Acad Dermatology Venereol 2006; 20 (10): 1307–13. DOI: 10.1111/j.1468-3083.2006.01807.x
19. Evans EGV, Bodman B, Williamson DM et al. Comparison of terbinafine and clotrimazole in treating tinea pedis. Br Med J 1993; 307 (6905): 645–7. DOI: 10.1136/bmj.307.6905.645
2. Al Hasan M, Fitzgerald SM, Saoudian M, Krishnaswamy G. Dermatology for the practicing allergist: Tinea pedis and its complications. Clin Mol Allergy 2004; 2 (1): 5. DOI: 10.1186/1476-7961-2-5
3. Sokolova TV, Maliarchuk TA. Epidemiologiia mikozov stop (Obzor literatury). Epidemiologiia i vaktsinoprofilaktika. 2015; 13 (1): 70–4 (in Russian).
4. Hay RJ, Campbell CK, Wingfield R, Clayton YM. A comparative study of dermatophytosis in coal miners and dermatological outpatients. Br J Ind Med 1983; 40 (3): 353–5. DOI: 10.1136/oem.40.3.353
5. Noguchi H, Hiruma M, Kawada A et al. Tinea pedis in members of the Japanese Self-defence Forces: relationships of its prevalence and its severity with length of military service and width of interdigital spaces. Mycoses 38 (11–12): 494–9. http://www.ncbi.nlm.nih.gov/pubmed/8720203
6. Lacroix C, Baspeyras M, de La Salmonière P et al. Tinea pedis in European marathon runners.
J Eur Acad Dermatol Venereol 2002; 16 (2): 139–42. DOI: 10.1046/j.1468-3083.2002.00400.x
7. Djeridane A, Djeridane Y, Ammar-Khodja A. Epidemiological and aetiological study on tinea pedis and onychomycosis in Algeria. Mycoses 2006; 49 (3): 190–6. DOI: 10.1111/j.1439-0507.2006.01230.x
8. Dhib I, Fathallah A, Yaacoub A et al. Clinical and mycological features of onychomycosis in central Tunisia: a 22 years retrospective study (1986–2007). Mycoses 2013; 56 (3): 273–80. DOI: 10.1111/myc.12016
9. Drakensjö IT, Chryssanthou E. Epidemiology of dermatophyte infections in Stockholm, Sweden:
a retrospective study from 2005–2009. Med Mycol 2011; 49 (5): 484–8. DOI: 10.3109/13693786.2010.540045
10. Alvarez MI, González LÁ, Castro LÁ. Onychomycosis in Cali, Colombia. Mycopathologia 2004;
158 (2): 181–6. DOI: 10.1023/B: MYCO.0000041866.85314.e4
11. Rukavishnikova VM. Mycoses of the feet. Moscow: Elix Kom, 2003 (in Russian).
12. Iakovlev A.B. Effektivnost' i bezopasnost' terbinafina pri kombinirovannoi terapii raznykh klinicheskikh form mikoza stop. Effektivnaia farmakoterapiia. 2018; 21: 4–9 (in Russian).
13. Favre B, Ryder NS. Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother 1996; 40 (2): 443–7. DOI: 10.1128/aac.40.2.443
14. Sugiura M, Hata Y, Fukuda T et al. One-week application of terbinafine cream compared with four-week application in treatment of Tinea pedis. Nihon Ishinkin Gakkai Zasshi 2001; 42 (4): 223–8. DOI: 10.3314/jjmm.42.223
15. Ablon G, Rosen T, Spedale J. Comparative efficacy of naftifine, oxiconazole, and terbinafine in short-term treatment of tinea pedis. Int J Dermatol 1996; 35 (8): 591–3. DOI: 10.1111/j.1365-4362.1996.tb03668.x
16. Khamaganova I.V., Tsykin A.A. Rastvor terbinafina 1% plenkoobrazuiushchii v terapii u patsientov, dlitel'no stradaiushchikh mikozami stop. Med. sovet. 2019; 12: 132–5 (in Russian).
17. Li RY, Wang AP, Xu JH et al. Efficacy and safety of 1% terbinafine film-forming solution in Chinese patients with tinea pedis: a randomized, double-blind, placebo-controlled, multicenter, parallel-group study. Clin Drug Investig 2014; 34 (3): 223–30. DOI: 10.1007/s40261-014-0171-8
18. Ortonne J, Korting H, Viguié-Vallanet C et al. Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athlete’s foot): a randomized, double-blind, placebo-controlled study. J Eur Acad Dermatology Venereol 2006; 20 (10): 1307–13. DOI: 10.1111/j.1468-3083.2006.01807.x
19. Evans EGV, Bodman B, Williamson DM et al. Comparison of terbinafine and clotrimazole in treating tinea pedis. Br Med J 1993; 307 (6905): 645–7. DOI: 10.1136/bmj.307.6905.645
2. Al Hasan M, Fitzgerald SM, Saoudian M, Krishnaswamy G. Dermatology for the practicing allergist: Tinea pedis and its complications. Clin Mol Allergy 2004; 2 (1): 5. DOI: 10.1186/1476-7961-2-5
3. Соколова ТВ, Малярчук ТА. Эпидемиология микозов стоп (Обзор литературы). Эпидемиология и вакцинопрофилактика. 2015; 13 (1): 70–4.
[Sokolova TV, Maliarchuk TA. Epidemiologiia mikozov stop (Obzor literatury). Epidemiologiia i vaktsinoprofilaktika. 2015; 13 (1): 70–4 (in Russian).]
4. Hay RJ, Campbell CK, Wingfield R, Clayton YM. A comparative study of dermatophytosis in coal miners and dermatological outpatients. Br J Ind Med 1983; 40 (3): 353–5. DOI: 10.1136/oem.40.3.353
5. Noguchi H, Hiruma M, Kawada A et al. Tinea pedis in members of the Japanese Self-defence Forces: relationships of its prevalence and its severity with length of military service and width of interdigital spaces. Mycoses 38 (11–12): 494–9. http://www.ncbi.nlm.nih.gov/pubmed/8720203
6. Lacroix C, Baspeyras M, de La Salmonière P et al. Tinea pedis in European marathon runners.
J Eur Acad Dermatol Venereol 2002; 16 (2): 139–42. DOI: 10.1046/j.1468-3083.2002.00400.x
7. Djeridane A, Djeridane Y, Ammar-Khodja A. Epidemiological and aetiological study on tinea pedis and onychomycosis in Algeria. Mycoses 2006; 49 (3): 190–6. DOI: 10.1111/j.1439-0507.2006.01230.x
8. Dhib I, Fathallah A, Yaacoub A et al. Clinical and mycological features of onychomycosis in central Tunisia: a 22 years retrospective study (1986–2007). Mycoses 2013; 56 (3): 273–80. DOI: 10.1111/myc.12016
9. Drakensjö IT, Chryssanthou E. Epidemiology of dermatophyte infections in Stockholm, Sweden:
a retrospective study from 2005–2009. Med Mycol 2011; 49 (5): 484–8. DOI: 10.3109/13693786.2010.540045
10. Alvarez MI, González LÁ, Castro LÁ. Onychomycosis in Cali, Colombia. Mycopathologia 2004;
158 (2): 181–6. DOI: 10.1023/B: MYCO.0000041866.85314.e4
11. Рукавишникова ВМ. Микозы стоп. М.: Эликс Ком, 2003.
[Rukavishnikova VM. Mycoses of the feet. Moscow: Elix Kom, 2003 (in Russian).]
12. Яковлев А.Б. Эффективность и безопасность тербинафина при комбинированной терапии разных клинических форм микоза стоп. Эффективная фармакотерапия. 2018; 21: 4–9.
[Iakovlev A.B. Effektivnost' i bezopasnost' terbinafina pri kombinirovannoi terapii raznykh klinicheskikh form mikoza stop. Effektivnaia farmakoterapiia. 2018; 21: 4–9 (in Russian).]
13. Favre B, Ryder NS. Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother 1996; 40 (2): 443–7. DOI: 10.1128/aac.40.2.443
14. Sugiura M, Hata Y, Fukuda T et al. One-week application of terbinafine cream compared with four-week application in treatment of Tinea pedis. Nihon Ishinkin Gakkai Zasshi 2001; 42 (4): 223–8. DOI: 10.3314/jjmm.42.223
15. Ablon G, Rosen T, Spedale J. Comparative efficacy of naftifine, oxiconazole, and terbinafine in short-term treatment of tinea pedis. Int J Dermatol 1996; 35 (8): 591–3. DOI: 10.1111/j.1365-4362.1996.tb03668.x
16. Хамаганова И.В., Цыкин А.А. Раствор тербинафина 1% пленкообразующий в терапии у пациентов, длительно страдающих микозами стоп. Мед. совет. 2019; 12: 132–5.
[Khamaganova I.V., Tsykin A.A. Rastvor terbinafina 1% plenkoobrazuiushchii v terapii u patsientov, dlitel'no stradaiushchikh mikozami stop. Med. sovet. 2019; 12: 132–5 (in Russian).]
17. Li RY, Wang AP, Xu JH et al. Efficacy and safety of 1% terbinafine film-forming solution in Chinese patients with tinea pedis: a randomized, double-blind, placebo-controlled, multicenter, parallel-group study. Clin Drug Investig 2014; 34 (3): 223–30. DOI: 10.1007/s40261-014-0171-8
18. Ortonne J, Korting H, Viguié-Vallanet C et al. Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athlete’s foot): a randomized, double-blind, placebo-controlled study. J Eur Acad Dermatology Venereol 2006; 20 (10): 1307–13. DOI: 10.1111/j.1468-3083.2006.01807.x
19. Evans EGV, Bodman B, Williamson DM et al. Comparison of terbinafine and clotrimazole in treating tinea pedis. Br Med J 1993; 307 (6905): 645–7. DOI: 10.1136/bmj.307.6905.645
________________________________________________
2. Al Hasan M, Fitzgerald SM, Saoudian M, Krishnaswamy G. Dermatology for the practicing allergist: Tinea pedis and its complications. Clin Mol Allergy 2004; 2 (1): 5. DOI: 10.1186/1476-7961-2-5
3. Sokolova TV, Maliarchuk TA. Epidemiologiia mikozov stop (Obzor literatury). Epidemiologiia i vaktsinoprofilaktika. 2015; 13 (1): 70–4 (in Russian).
4. Hay RJ, Campbell CK, Wingfield R, Clayton YM. A comparative study of dermatophytosis in coal miners and dermatological outpatients. Br J Ind Med 1983; 40 (3): 353–5. DOI: 10.1136/oem.40.3.353
5. Noguchi H, Hiruma M, Kawada A et al. Tinea pedis in members of the Japanese Self-defence Forces: relationships of its prevalence and its severity with length of military service and width of interdigital spaces. Mycoses 38 (11–12): 494–9. http://www.ncbi.nlm.nih.gov/pubmed/8720203
6. Lacroix C, Baspeyras M, de La Salmonière P et al. Tinea pedis in European marathon runners.
J Eur Acad Dermatol Venereol 2002; 16 (2): 139–42. DOI: 10.1046/j.1468-3083.2002.00400.x
7. Djeridane A, Djeridane Y, Ammar-Khodja A. Epidemiological and aetiological study on tinea pedis and onychomycosis in Algeria. Mycoses 2006; 49 (3): 190–6. DOI: 10.1111/j.1439-0507.2006.01230.x
8. Dhib I, Fathallah A, Yaacoub A et al. Clinical and mycological features of onychomycosis in central Tunisia: a 22 years retrospective study (1986–2007). Mycoses 2013; 56 (3): 273–80. DOI: 10.1111/myc.12016
9. Drakensjö IT, Chryssanthou E. Epidemiology of dermatophyte infections in Stockholm, Sweden:
a retrospective study from 2005–2009. Med Mycol 2011; 49 (5): 484–8. DOI: 10.3109/13693786.2010.540045
10. Alvarez MI, González LÁ, Castro LÁ. Onychomycosis in Cali, Colombia. Mycopathologia 2004;
158 (2): 181–6. DOI: 10.1023/B: MYCO.0000041866.85314.e4
11. Rukavishnikova VM. Mycoses of the feet. Moscow: Elix Kom, 2003 (in Russian).
12. Iakovlev A.B. Effektivnost' i bezopasnost' terbinafina pri kombinirovannoi terapii raznykh klinicheskikh form mikoza stop. Effektivnaia farmakoterapiia. 2018; 21: 4–9 (in Russian).
13. Favre B, Ryder NS. Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother 1996; 40 (2): 443–7. DOI: 10.1128/aac.40.2.443
14. Sugiura M, Hata Y, Fukuda T et al. One-week application of terbinafine cream compared with four-week application in treatment of Tinea pedis. Nihon Ishinkin Gakkai Zasshi 2001; 42 (4): 223–8. DOI: 10.3314/jjmm.42.223
15. Ablon G, Rosen T, Spedale J. Comparative efficacy of naftifine, oxiconazole, and terbinafine in short-term treatment of tinea pedis. Int J Dermatol 1996; 35 (8): 591–3. DOI: 10.1111/j.1365-4362.1996.tb03668.x
16. Khamaganova I.V., Tsykin A.A. Rastvor terbinafina 1% plenkoobrazuiushchii v terapii u patsientov, dlitel'no stradaiushchikh mikozami stop. Med. sovet. 2019; 12: 132–5 (in Russian).
17. Li RY, Wang AP, Xu JH et al. Efficacy and safety of 1% terbinafine film-forming solution in Chinese patients with tinea pedis: a randomized, double-blind, placebo-controlled, multicenter, parallel-group study. Clin Drug Investig 2014; 34 (3): 223–30. DOI: 10.1007/s40261-014-0171-8
18. Ortonne J, Korting H, Viguié-Vallanet C et al. Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athlete’s foot): a randomized, double-blind, placebo-controlled study. J Eur Acad Dermatology Venereol 2006; 20 (10): 1307–13. DOI: 10.1111/j.1468-3083.2006.01807.x
19. Evans EGV, Bodman B, Williamson DM et al. Comparison of terbinafine and clotrimazole in treating tinea pedis. Br Med J 1993; 307 (6905): 645–7. DOI: 10.1136/bmj.307.6905.645
Авторы
И.С. Максимов
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
maximov.is@mail.ru
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
maximov.is@mail.ru
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
maximov.is@mail.ru
________________________________________________
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
maximov.is@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.